Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow Reinvestment Rate
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow Reinvestment Rate of 0.21x as of September 2025, reinvesting ₩1.42 Billion (capex ₩1.39 Billion plus investments ₩35.01 Million) from operating cash flow of ₩6.82 Billion. Check 061250 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hwail Pharmaceutical Co.Ltd Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Hwail Pharmaceutical Co.Ltd across 10 annual periods. Explore 061250 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year capital reinvestment analysis for Hwail Pharmaceutical Co.Ltd. For live market cap and broader valuation context, see 061250 market cap.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.24x | ₩84.20 Billion | ₩11.63 Billion | ₩34.63 Billion | ▲ +132.8% |
| 2023 | 3.11x | ₩21.84 Billion | ₩7.02 Billion | ₩2.10 Billion | ▲ +59.1% |
| 2021 | 1.95x | ₩39.26 Billion | ₩20.09 Billion | ₩2.47 Billion | ▲ +564.1% |
| 2019 | 0.29x | ₩1.09 Billion | ₩3.69 Billion | ₩1.09 Billion | ▲ +36.1% |
| 2018 | 0.22x | ₩1.55 Billion | ₩7.17 Billion | ₩1.55 Billion | ▲ +250.9% |
| 2017 | 0.06x | ₩513.62 Million | ₩8.34 Billion | ₩513.62 Million | ▼ -91.9% |
| 2016 | 0.76x | ₩7.29 Billion | ₩9.58 Billion | ₩413.00 Million | ▼ -52.4% |
| 2013 | 1.60x | ₩11.16 Billion | ₩6.97 Billion | ₩9.18 Billion | ▼ -79.2% |
| 2012 | 7.69x | ₩7.72 Billion | ₩1.00 Billion | ₩7.72 Billion | ▲ +1034.5% |
| 2011 | 0.68x | ₩5.32 Billion | ₩7.86 Billion | ₩5.32 Billion | — |